PBE News and Press, Invesco Dynamic Biotech & Genome From 04/01/24

2024-04-01 10:30:00 ET Summary Biotechnology and genomics sector has not performed well in recent years, making it an attractive investment opportunity. The Invesco Biotechnology & Genome ETF offers comprehensive exposure to the biotech sector with a diversified portfolio. ...

2024-03-30 03:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-25 05:22:18 ET Summary ARK Genomic Revolution ETF warrants a hold rating due to multiple roadblocks preventing solid returns, including underdeveloped technology, legal hurdles, and unresolved ethical dilemmas. ARKG has a relatively high expense ratio with no dividend yiel...

2024-03-22 11:15:00 ET Summary A positive January for U.S. stocks is typically a prelude to a positive year, with our analysis finding the correlation to hold 80% of the time since 1928. Stocks look well-positioned to outperform bonds and cash again this year, but high valuations ...

2024-03-22 10:22:28 ET More on Invesco Dynamic Biotechnology & Genome ETF Seeking Alpha’s Quant Rating on Invesco Dynamic Biotechnology & Genome ETF Dividend scorecard for Invesco Dynamic Biotechnology & Genome ETF Read the full article on Seekin...

2024-03-20 01:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-19 02:50:00 ET Summary Typically, a back-up in rates has led to a sell-off in stocks. We believe the current environment is different for three reasons: the degree of the move in rates, current economic cycle, and strength of mega-cap technology. In this environment, we wo...

2024-03-13 10:10:00 ET Summary Jeff Hirsch, editor-in-chief of The Stock Trader’s Almanac, and Carter Worth, CEO and founder of Worth Charting, discuss their outlook for 2024 with MoneyShow's Mike Larson. Jeff expects a strong year for stocks, with gains of 8-15% broadly sp...

2024-03-09 03:59:00 ET Summary Jared Ablass, Vice President, Portfolio Research at TD Asset Management, speaks with Greg Bonnell about how the biotech sector could benefit once rates start to come down. Why beaten down Biotech stocks could be ready for a healthy recovery. Biot...

2024-03-06 11:25:10 ET Over the past 3 months the biotech space is +30.4% and has only been outperformed by semiconductors, computer processing hardware and the computer peripherals industries. Additionally, the biotech sector is +13.6% in 2024, outdoing all of the major market aver...